8-K filed May 18, 2026 at 09:06 ET
Neurocrine Biosciences completed its acquisition of Soleno Therapeutics on May 18, 2026, paying $53.00 per share in cash. The tender offer closed with 46,356,114 shares (88.9% of outstanding) tendered, followed by a short-form merger under Section 251(h) of the DGCL. SLNO common stock has been delisted from Nasdaq and the company will deregister its securities. This filing confirms the deal has closed, existing SLNO shareholders who did not tender in the offer will receive $53.00 per share in the merger.